Clinical Trial Update: Effects Of CP-690,550 (Tasocitinib) On Cholesterol Metabolism In Patients With Active Rheumatoid Arthritis [Phase 1]

View source ↗

Summary

This report covers a Phase 1 study by Pfizer examining the effect of tasocitinib (CP-690,550) on cholesterol metabolism in patients with active rheumatoid arthr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Drugs mentioned

• Tofacitinib (tofacitinib)

Snippet

Sponsor: Pfizer | Conditions: Rheumatoid Arthritis | Phase 1 | Status: COMPLETED | Results posted: 2013-01-23